Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Silver North Intersects 1.83 metres True Width of 1,088 g/t Silver, 3.90 g/t Gold (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Xilio Therapeutics Inc XLO

Healthcare Biotechnology
Xilio Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is engaged in discovering and developing tumor-activated immuno-oncology (I-O) therapies with the goal of improving outcomes for people living with cancer without the systemic side effects of current I-O treatments. The Company is using its proprietary platform to advance a pipeline of novel, tumor-activated... see more

Recent & Breaking News (NDAQ:XLO)

Xilio Therapeutics Announces Promotion of Katarina Luptakova, M.D., to Chief Medical Officer and Scott Coleman, Ph.D., to Chief Development Officer

GlobeNewswire September 5, 2023

Xilio Therapeutics to Present at Morgan Stanley 21st Annual Global Healthcare Conference

GlobeNewswire September 5, 2023

Xilio Therapeutics Announces Pipeline and Business Updates and Second Quarter 2023 Financial Results

GlobeNewswire August 14, 2023

Xilio Therapeutics Announces Promotion of Chris Frankenfield to Chief Operating Officer

GlobeNewswire August 3, 2023

Xilio Therapeutics Announces Preliminary Clinical Data from Phase 1 Trial of XTX101, a Tumor-Activated, Fc-Enhanced Anti-CTLA-4, in Patients with Advanced Solid Tumors

GlobeNewswire May 25, 2023

Xilio Therapeutics Announces Pipeline and Business Updates and First Quarter 2023 Financial Results

GlobeNewswire May 9, 2023

Xilio Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire April 3, 2023

Xilio Therapeutics Announces Pipeline and Business Updates for the Fourth Quarter and Full Year 2022 Financial Results

GlobeNewswire March 2, 2023

Xilio Therapeutics to Present at Upcoming Investor Conferences

GlobeNewswire February 27, 2023

Xilio Therapeutics to Present at the Citi 2023 Virtual Oncology Leadership Summit

GlobeNewswire February 16, 2023

Xilio Therapeutics to Present at the Guggenheim Healthcare Talks Oncology Day

GlobeNewswire February 2, 2023

Xilio Therapeutics to Host Live Virtual Program Spotlighting XTX301, a Tumor-Activated IL-12

GlobeNewswire November 23, 2022

Xilio Therapeutics Announces Pipeline and Business Updates and Third Quarter 2022 Financial Results

GlobeNewswire November 9, 2022

Xilio Therapeutics to Present at Cowen 6th Annual 'IO Next' Summit

GlobeNewswire November 4, 2022

Xilio Therapeutics to Present at Guggenheim Nantucket Therapeutics Conference

GlobeNewswire September 22, 2022

Xilio Therapeutics Appoints Tomas J. Heyman to Board of Directors

GlobeNewswire September 15, 2022

Xilio Therapeutics to Present at Morgan Stanley 20th Annual Global Healthcare Conference

GlobeNewswire September 6, 2022

Xilio Therapeutics Announces Encouraging Preliminary Phase 1 Dose-Escalation Data for XTX101, a Tumor-Selective Anti-CTLA-4, and Reports Pipeline and Business Updates and Second Quarter 2022 Financial Results

GlobeNewswire August 9, 2022

Xilio Therapeutics Announces Promotion of Martin Huber, M.D., to President

GlobeNewswire June 16, 2022

Xilio Therapeutics to Present at the H.C. Wainwright Global Investment Conference

GlobeNewswire May 18, 2022